Barclays initiated coverage on shares of Shire (LON:SHP) in a report released on Thursday, February 1st. The firm set an “equal weight” rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also recently commented on the stock. Shore Capital reaffirmed a “buy” rating on shares of Shire in a report on Thursday, October 26th. Goldman Sachs Group reaffirmed a “conviction-buy” rating on shares of Shire in a report on Tuesday, October 17th. Morgan Stanley lowered their price target on shares of Shire from GBX 5,800 ($81.32) to GBX 5,700 ($79.92) and set an “overweight” rating on the stock in a report on Thursday, October 12th. Citigroup reaffirmed a “buy” rating and issued a GBX 5,500 ($77.12) price target on shares of Shire in a report on Friday, December 8th. Finally, lowered their price target on shares of Shire from GBX 4,480 ($62.82) to GBX 4,050 ($56.79) and set a “hold” rating on the stock in a report on Tuesday, October 31st. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of GBX 5,244.44 ($73.53).
Shire (LON SHP) traded down GBX 74 ($1.04) during trading on Thursday, hitting GBX 3,093.50 ($43.37). 2,438,482 shares of the company’s stock traded hands, compared to its average volume of 2,580,000. The company has a market cap of $28,280.00 and a PE ratio of 2,416.80. Shire has a 1 year low of GBX 3,081 ($43.20) and a 1 year high of GBX 5,067 ($71.05).
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/02/04/barclays-begins-coverage-on-shire-shp.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.